123 results
8-K
EX-99.1
ABBV
Abbvie Inc
26 Apr 24
AbbVie Reports First-Quarter 2024 Financial Results
7:43am
(atogepant) to prevent chronic and episodic migraine. The overall long-term safety results were consistent with the known safety profile of Qulipta … in chronic and episodic migraine, and no new safety signals were identified. These results also support improvements in key efficacy outcomes, including
424B5
ABBV
Abbvie Inc
26 Feb 24
Prospectus supplement for primary offering
6:12am
(moderate to severe)
North America, European Union
Plaque psoriasis (moderate to severe chronic)
North America, European Union
Juvenile idiopathic arthritis … separate designations. Imbruvica currently is approved for the treatment of adult patients with blood cancers such as chronic lymphocytic leukemia (“CLL
424B5
7vl gdggxw8
21 Feb 24
Prospectus supplement for primary offering
8:39am
8-K
EX-99.1
el7fr
27 Oct 23
AbbVie Reports Third-Quarter 2023 Financial Results
7:49am
8-K
EX-99.1
6wjx849 7qxh402now
27 Jul 23
AbbVie Reports Second-Quarter 2023 Financial Results
7:45am
8-K
EX-99.1
zuj5uj
27 Apr 23
AbbVie Reports First-Quarter 2023 Financial Results
7:36am
8-K
EX-99.1
z8tkd mj4uf42ttpg0c
28 Oct 22
AbbVie Reports Third-Quarter 2022 Financial Results
7:48am
8-K
EX-99.1
0ty8u
29 Jul 22
AbbVie Reports Second-Quarter 2022 Financial Results
7:49am
8-K
EX-99.1
ttkj8
29 Apr 22
AbbVie Reports First-Quarter 2022 Financial Results
9:00am
8-K
EX-99.1
ih5d3h
29 Apr 22
AbbVie Reports First-Quarter 2022 Financial Results
7:45am